8:00 am Morning Refreshments & Check In
8:55 am Chair’s Opening Remarks
UNLOCKING THE POTENTIAL: PRECLINICAL CONSIDERATIONS TO ENHANCE CANNABINOID DELIVERABILTY & SUSTAINABILTY
9:00 am The Potential of Controllable CBD-THC Mixtures for the Treatment of Chronic Pain
Synopsis
- The ability to precisely control THC/CBD ratio to more accurately target pain symptoms
- Ensuring good manufacturing practice (GMP) of synthetic API for consistent, high quality drug synthesis
- Analyzing the efficiency of this process compared to extraction
- Developing a drug-delivery device to tailor dosage ratios for personalised and patientcentric treatment
9:30 am Patient-Centric Innovation in Cannabinoid Medicine Development
10:00 am Re-Purposing Dronabinol Using Proprietary Formulations for New Therapeutic Indications, Specifically Obstructive Sleep Apnea (OSA)
Synopsis
- Looking at Dronabinol’s potential to stabilize respiratory patterns and augment upper airway muscles
- Introducing drug formulation innovation in the form of proprietary lipid nanoparticle technology to enhance solubility and absorption
- Enhancing Dronabinol stability and ease of manufacturing to support commercial scale
10:30 am Speed Networking
Synopsis
Make the most of your unique networking opportunity at the only industry-focused and scientific event for cannabinoid, CB1 and CB2 drug developers. Reconnect with friendly faces and meet brand new R&D scientists and C-Level leaders from new companies joining the space to forge fruitful relationships and ignite potential collaborations.
11:00 am Morning Break & Refreshments
CB1 UNLEASHED: FROM PRECLINICAL INSIGHTS TO THERAPEUTIC BREAKTHROUGHS
11:30 am Advancing a Neutral Antagonist of the CB1 Receptor in Preclinical Development for Alcohol, Opioid & Cocaine Use Disorders
Synopsis
- Looking at how AM6527, a neutral CB1 receptor antagonist, effectively inhibits heroin and cocaine self-administration under progressive-ratio reinforcement schedules in addiction models
- Discussing behavioural effects and tolerance development in preclinical findings
- Analyzing safety profile and future directions, comparing to Rimonabant suggests it may offer a safer alternative for treating substance use disorders
12:00 pm ART27.13, a Peripherally Restricted CB1 Agonist Under Clinical Investigation Targeting Cancer Anorexia & Cachexia Syndrome (CACS)
Synopsis
- Exploring the scientific and clinical validation of ART27.13, a dual CB1/CB2 agonist, through Phase 1 results and its progression to the Phase 2a CAReS Trial for treating CACS
- Analyzing the formulation of ART27.13, its unique chemical properties, and the intellectual property supporting its peripheral receptor selectivity
- Assessing the unmet need in cancer anorexia and cachexia syndrome (CACS) and the potential impact of ART27.13 in addressing this gap
12:30 pm Lunch & Networking Break & Scientific Poster Session
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of preclinical, translational, and clinical scientists eager to hear the latest advancements in CB1, CB2, and cannabinoid therapeutic development, you will have the opportunity to display a poster presenting your own work and innovations.
NAVIGATING THE REGULATORY LANDSCAPE: POLICIES, OVERSIGHT, GMP & SAFETY FOR CANNABINOID RESEARCH
1:45 pm Navigating Novel Cannabinoid Regulatory Pathways During Preclinical & Clinical Research
Synopsis
- What unique challenges does the industry face when complying with regulations related to novel cannabinoids?
- What can we learn from previous cannabinoid drug approvals to aid the acceleration of new approvals?
- How do we address chemical and biological contaminants in cannabinoid products while adhering to regulations
- What recent advancements of analytical methodology can we take advantage of to comply with regulatory guidelines?
- How do FDA, USP, and ASTM regulations intersect and diverge concerning cannabinoids?
2:15 pm Biomimetic Cannabinoid Production to Address Agricultural Limitations
Synopsis
- Latest developments in a semi-synthesis program that yields pure acidic and decarboxylated forms of many known phytocannabinoids
- Why acid or “A”-type cannabinoids may be superior ingredients in the formulation of new medicines
- The importance of an abundant supply and consistent quality in achieving drug scalability post discovery and development
2:25 pm Afternoon Break & Refreshments
COLLABORATION & EXPLORATION: UNITING FORCES IN CANNABINOID DRUG DEVELOPMENT & EXPANDING THERAPEUTIC TARGETS
3:15 pm Selective Endocannabinoid Re-uptake Inhibitors (SERIs): A New Class of ECS Modulators for Safe & Effective Treatment of Neuropsychiatric Disorders
Synopsis
- Presenting the mode of action of SERIs to inhibit eCB re-uptake across plasma membranes by targeting a newly identified protein in the ECS
- SERIs represent a new class of ECS modulators characterized by a distinctive pharmacology profile within the ECS
- Showcasing SYT-510, a clinical candidate of the SERI class.
3:45 pm Panel Discussion: Overcoming Challenges for Pharmaceutical Engagement in R&D for Cannabinoid & Endocannabinoid System Targeting Drug Development
Synopsis
- How can pharma work with other stakeholders to de-risk investment in cannabinoid drug development?
- What actions can be taken to de-stigmatise cannabinoid drug development across large pharma?
- How have the first few breakthrough regulatory approvals paved the way for more widely accepted cannabinoid drug development within pharma?
- How can emerging technologies and innovative approaches within pharma accelerate the development and commercialization of cannabinoid-based therapeutics?